Published in FASEB J on April 06, 2010
Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation (2014) 1.83
Neuroprotection and progenitor cell renewal in the injured adult murine retina requires healing monocyte-derived macrophages. J Exp Med (2011) 1.80
IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron (2015) 1.58
IL-4 in the brain: a cytokine to remember. J Immunol (2012) 1.34
Lipopolysaccharide-induced interleukin (IL)-4 receptor-α expression and corresponding sensitivity to the M2 promoting effects of IL-4 are impaired in microglia of aged mice. Brain Behav Immun (2011) 1.27
The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer's disease brain. Arch Immunol Ther Exp (Warsz) (2012) 1.23
Cytokine dysregulation in autism spectrum disorders (ASD): possible role of the environment. Neurotoxicol Teratol (2012) 1.21
Microglia and macrophages differentially modulate cell death after brain injury caused by oxygen-glucose deprivation in organotypic brain slices. Glia (2013) 1.05
Eliminating microglia in Alzheimer's mice prevents neuronal loss without modulating amyloid-β pathology. Brain (2016) 1.01
FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer's disease and has therapeutic implications for neurocognitive disorders. Proc Natl Acad Sci U S A (2011) 1.00
AAV serotype 2/1-mediated gene delivery of anti-inflammatory interleukin-10 enhances neurogenesis and cognitive function in APP+PS1 mice. Gene Ther (2011) 0.99
Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition. Mol Neurodegener (2012) 0.97
Modulation of adult-born neurons in the inflamed hippocampus. Front Cell Neurosci (2013) 0.94
Function of microglia and macrophages in secondary damage after spinal cord injury. Neural Regen Res (2014) 0.94
Modulation of learning and memory by cytokines: signaling mechanisms and long term consequences. Neurobiol Learn Mem (2014) 0.91
Review: experimental manipulations of microglia in mouse models of Alzheimer's pathology: activation reduces amyloid but hastens tau pathology. Neuropathol Appl Neurobiol (2013) 0.89
Whole-genome sequencing suggests a chemokine gene cluster that modifies age at onset in familial Alzheimer's disease. Mol Psychiatry (2015) 0.89
Anesthetic modulation of neuroinflammation in Alzheimer's disease. Curr Opin Anaesthesiol (2011) 0.86
Determining the role of IL-4 induced neuroinflammation in microglial activity and amyloid-β using BV2 microglial cells and APP/PS1 transgenic mice. J Neuroinflammation (2015) 0.86
Understanding the neurobiology of CD200 and the CD200 receptor: a therapeutic target for controlling inflammation in human brains? Future Neurol (2013) 0.85
Targeting innate immunity for neurodegenerative disorders of the central nervous system. J Neurochem (2016) 0.85
CCL2 affects β-amyloidosis and progressive neurocognitive dysfunction in a mouse model of Alzheimer's disease. Neurobiol Aging (2012) 0.85
Is there a causal link between inflammation and dementia? Biomed Res Int (2013) 0.84
Adeno-Associated Virus-Based Gene Therapy for CNS Diseases. Hum Gene Ther (2016) 0.84
G-protein-coupled receptors in adult neurogenesis. Pharmacol Rev (2012) 0.83
The dual roles of cytokines in Alzheimer's disease: update on interleukins, TNF-α, TGF-β and IFN-γ. Transl Neurodegener (2016) 0.82
Non-transcriptional regulation of NLRP3 inflammasome signaling by IL-4. Immunol Cell Biol (2015) 0.82
Xanthoceraside attenuates amyloid β peptide₂₅₋₃₅-induced learning and memory impairments in mice. Psychopharmacology (Berl) (2011) 0.82
Brain metabolic stress and neuroinflammation at the basis of cognitive impairment in Alzheimer's disease. Front Aging Neurosci (2015) 0.82
The anti-inflammatory glycoprotein, CD200, restores neurogenesis and enhances amyloid phagocytosis in a mouse model of Alzheimer's disease. Neurobiol Aging (2015) 0.82
The effect of HIV protease inhibitors on amyloid-β peptide degradation and synthesis in human cells and Alzheimer's disease animal model. J Neuroimmune Pharmacol (2011) 0.80
IL-4, JAK-STAT signaling, and pain. JAKSTAT (2014) 0.79
Glycogen synthase kinase-3β: a mediator of inflammation in Alzheimer's disease? Int J Alzheimers Dis (2011) 0.79
Optimized turmeric extract reduces β-Amyloid and phosphorylated Tau protein burden in Alzheimer's transgenic mice. Curr Alzheimer Res (2012) 0.78
Activation of the α7 nicotinic receptor promotes lipopolysaccharide-induced conversion of M1 microglia to M2. Am J Transl Res (2017) 0.77
Commentary: IL-4 and IL-13 receptors and signaling. Cytokine (2015) 0.77
Gene therapy for misfolding protein diseases of the central nervous system. Neurotherapeutics (2013) 0.77
Dab2 attenuates brain injury in APP/PS1 mice via targeting transforming growth factor-beta/SMAD signaling. Neural Regen Res (2014) 0.77
Arginase 1+ microglia reduce Aβ plaque deposition during IL-1β-dependent neuroinflammation. J Neuroinflammation (2015) 0.77
Disrupted-in-Schizophrenia-1 Attenuates Amyloid-β Generation and Cognitive Deficits in APP/PS1 Transgenic Mice by Reduction of β-Site APP-Cleaving Enzyme 1 Levels. Neuropsychopharmacology (2015) 0.76
Cathepsin B Improves ß-Amyloidosis and Learning and Memory in Models of Alzheimer's Disease. J Neuroimmune Pharmacol (2016) 0.75
Interleukin-4 Protects Dopaminergic Neurons In vitro but Is Dispensable for MPTP-Induced Neurodegeneration In vivo. Front Mol Neurosci (2017) 0.75
LW-AFC, a new formula derived from Liuwei Dihuang decoction, ameliorates behavioral and pathological deterioration via modulating the neuroendocrine-immune system in PrP-hAβPPswe/PS1(ΔE9) transgenic mice. Alzheimers Res Ther (2016) 0.75
Construction of AAV-rat-IL4 and Evaluation of its Modulating Effect on Aβ (1-42)-Induced Proinflammatory Cytokines in Primary Microglia and the B92 Cell Line by Quantitative PCR Assay. Jundishapur J Microbiol (2016) 0.75
Spinal Cord Injury Impairs Neurogenesis and Induces Glial Reactivity in the Hippocampus. Neurochem Res (2017) 0.75
Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol (1986) 35.41
Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science (1996) 19.72
Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature (2002) 19.36
Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med (2008) 17.09
A specific amyloid-beta protein assembly in the brain impairs memory. Nature (2006) 16.19
Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A (1998) 16.04
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 12.95
Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci (2004) 9.73
Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci (2005) 9.17
The molecular pathology of Alzheimer's disease. Neuron (1991) 8.21
Tricine-SDS-PAGE. Nat Protoc (2006) 7.89
A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2001) 7.35
Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med (1998) 5.78
Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature (1996) 5.50
Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias. Trends Neurosci (1999) 5.15
Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron (2003) 4.39
Efficacy of doublecortin as a marker to analyse the absolute number and dendritic growth of newly generated neurons in the adult dentate gyrus. Eur J Neurosci (2004) 2.86
Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation (2004) 2.67
Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A (2003) 2.58
Biological properties of interleukin 10. J Clin Immunol (1992) 2.50
Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol (2006) 2.33
Protective effects of NSAIDs on the development of Alzheimer disease. Neurology (2008) 2.21
Th1 and Th2 subsets: paradigms lost? Immunol Today (1995) 2.21
Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol (2007) 2.05
Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci (2008) 2.01
Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat Neurosci (2002) 1.97
Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc Natl Acad Sci U S A (2006) 1.92
Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. J Cell Biol (2007) 1.90
Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology. J Clin Invest (2006) 1.87
The Dopamine/D1 receptor mediates the phosphorylation and inactivation of the protein tyrosine phosphatase STEP via a PKA-dependent pathway. J Neurosci (2000) 1.63
Functions of IL-4 and control of its expression. Crit Rev Immunol (1997) 1.61
CD200 ligand receptor interaction modulates microglial activation in vivo and in vitro: a role for IL-4. J Neurosci (2007) 1.51
Synaptic plasticity: one STEP at a time. Trends Neurosci (2006) 1.51
Dose and promoter effects of adeno-associated viral vector for green fluorescent protein expression in the rat brain. Exp Neurol (2002) 1.49
Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. J Cell Mol Med (2008) 1.48
Overexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid deposition. Am J Pathol (2005) 1.46
Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J Clin Invest (2005) 1.45
Set back to Alzheimer vaccine studies. Nat Med (2002) 1.43
IGF-I prevents glutamate-induced motor neuron programmed cell death. Neurobiol Dis (2004) 1.39
The p75 neurotrophin receptor promotes amyloid-beta(1-42)-induced neuritic dystrophy in vitro and in vivo. J Neurosci (2009) 1.31
Interleukin-10 attenuates production of HSV-induced inflammatory mediators by human microglia. Glia (2004) 1.26
IL-13 induces phosphorylation and activation of JAK2 Janus kinase in human colon carcinoma cell lines: similarities between IL-4 and IL-13 signaling. J Immunol (1996) 1.26
Cytokine-mediated inhibition of fibrillar amyloid-beta peptide degradation by human mononuclear phagocytes. J Immunol (2008) 1.23
Interleukin-10: biology, role in inflammation and autoimmunity. Ann Allergy Asthma Immunol (1997) 1.23
Abeta 1-42 induces mild endoplasmic reticulum stress in an aggregation state-dependent manner. Antioxid Redox Signal (2007) 1.23
IL-4-induced selective clearance of oligomeric beta-amyloid peptide(1-42) by rat primary type 2 microglia. J Immunol (2008) 1.16
Downregulation of IL-4-induced signalling in hippocampus contributes to deficits in LTP in the aged rat. Neurobiol Aging (2005) 1.16
IL-4 attenuates the neuroinflammation induced by amyloid-beta in vivo and in vitro. J Neurochem (2007) 1.14
IL-4, IL-10 and IL-13 modulate A beta(1--42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line. J Neuroimmunol (2001) 1.12
Effects of adenoviral-mediated gene transfer of interleukin-10, interleukin-4, and transforming growth factor-beta on the survival of axotomized retinal ganglion cells. Neuroscience (2004) 1.09
Amino acid copolymer-specific IL-10-secreting regulatory T cells that ameliorate autoimmune diseases in mice. Proc Natl Acad Sci U S A (2008) 1.04
Reduced pathology and improved behavioral performance in Alzheimer's disease mice vaccinated with HSV amplicons expressing amyloid-beta and interleukin-4. Mol Ther (2008) 1.02
Interleukin-10: potential benefits and possible risks in clinical infectious diseases. Clin Infect Dis (1998) 1.00
AAV1/2-mediated CNS gene delivery of dominant-negative CCL2 mutant suppresses gliosis, beta-amyloidosis, and learning impairment of APP/PS1 mice. Mol Ther (2009) 0.98
Oral treatment of mice with copolymer 1 (glatiramer acetate) results in the accumulation of specific Th2 cells in the central nervous system. J Neuroimmunol (2002) 0.95
Immunization with amyloid-beta using GM-CSF and IL-4 reduces amyloid burden and alters plaque morphology. Neurobiol Dis (2006) 0.87
Prevention of TGF-beta-induced apoptosis by interlukin-4 through Akt activation and p70S6K survival signaling pathways. Apoptosis (2007) 0.87
Interleukin-4 and interleukin-10 modulate nuclear factor kappaB activity and nitric oxide synthase-2 expression in Theiler's virus-infected brain astrocytes. J Neurochem (2002) 0.85
A catalytically active Jak2 is required for the angiotensin II-dependent activation of Fyn. J Biol Chem (1999) 0.81
Interleukin-4 blocks thapsigargin-induced cell death in rat rod photoreceptors: involvement of cAMP/PKA pathway. J Neurosci Res (2009) 0.79
A call for transparent reporting to optimize the predictive value of preclinical research. Nature (2012) 14.63
Chronic traumatic encephalopathy in blast-exposed military veterans and a blast neurotrauma mouse model. Sci Transl Med (2012) 6.27
The spectrum of disease in chronic traumatic encephalopathy. Brain (2012) 5.10
Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2007) 2.43
Human immunodeficiency virus type 1 pathobiology studied in humanized BALB/c-Rag2-/-gammac-/- mice. J Virol (2006) 2.24
Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood (2006) 2.13
Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol (2007) 2.05
Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2004) 2.01
Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One (2008) 1.99
Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J Immunol (2009) 1.85
Rho-mediated regulation of tight junctions during monocyte migration across the blood-brain barrier in HIV-1 encephalitis (HIVE). Blood (2006) 1.85
Oxidative stress and the pathogenesis of neurodegenerative disorders. Int Rev Neurobiol (2007) 1.84
Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease. J Leukoc Biol (2007) 1.80
CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease. J Neuroimmune Pharmacol (2012) 1.78
HIV-1 gp120 compromises blood-brain barrier integrity and enhances monocyte migration across blood-brain barrier: implication for viral neuropathogenesis. J Cereb Blood Flow Metab (2006) 1.72
NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. Nanomedicine (Lond) (2009) 1.72
Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice. PLoS One (2008) 1.65
Mononuclear phagocyte immunity and the neuropathogenesis of HIV-1 infection. J Leukoc Biol (2003) 1.62
A functional transsulfuration pathway in the brain links to glutathione homeostasis. J Biol Chem (2006) 1.61
STAT1 signaling modulates HIV-1-induced inflammatory responses and leukocyte transmigration across the blood-brain barrier. Blood (2007) 1.60
Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J Immunol (2010) 1.57
Phosphorylation of claudin-5 and occludin by rho kinase in brain endothelial cells. Am J Pathol (2008) 1.55
NanoART, neuroAIDS and CNS drug delivery. Nanomedicine (Lond) (2009) 1.55
Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. Blood (2005) 1.54
HIV-1-associated dementia: a basic science and clinical perspective. AIDS Read (2002) 1.54
Macrophage endocytic trafficking of antiretroviral nanoparticles. Nanomedicine (Lond) (2011) 1.52
Quantitative diffusion tensor imaging detects dopaminergic neuronal degeneration in a murine model of Parkinson's disease. Neurobiol Dis (2007) 1.52
Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease. Clin Neurosci Res (2006) 1.50
A coat of many colors: neuroimmune crosstalk in human immunodeficiency virus infection. Neuron (2009) 1.48
HIV-1-associated dementia: a metabolic encephalopathy perpetrated by virus-infected and immune-competent mononuclear phagocytes. J Acquir Immune Defic Syndr (2002) 1.46
Overexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid deposition. Am J Pathol (2005) 1.46
Molecular mechanisms involving sigma receptor-mediated induction of MCP-1: implication for increased monocyte transmigration. Blood (2010) 1.44
Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics. J Neuroimmune Pharmacol (2010) 1.42
Biochemical and biologic characterization of exosomes and microvesicles as facilitators of HIV-1 infection in macrophages. J Immunol (2012) 1.42
Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology (2006) 1.41
HIV-1-infected and/or immune activated macrophages regulate astrocyte SDF-1 production through IL-1beta. Glia (2006) 1.40
A macrophage-nanozyme delivery system for Parkinson's disease. Bioconjug Chem (2007) 1.38
Nanotechnology: a focus on nanoparticles as a drug delivery system. J Neuroimmune Pharmacol (2006) 1.37
Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease. J Neurochem (2007) 1.35
Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment. J Proteome Res (2007) 1.35
Contrasting pathology of the stress granule proteins TIA-1 and G3BP in tauopathies. J Neurosci (2012) 1.34
Cell-mediated drug delivery. Expert Opin Drug Deliv (2011) 1.33
Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. AIDS (2012) 1.32
HIV-1 neuroimmunity in the era of antiretroviral therapy. Neurobiol Dis (2010) 1.32
The comorbidity of HIV-associated neurocognitive disorders and Alzheimer's disease: a foreseeable medical challenge in post-HAART era. J Neuroimmune Pharmacol (2008) 1.31
Facilitated monocyte-macrophage uptake and tissue distribution of superparmagnetic iron-oxide nanoparticles. PLoS One (2009) 1.31
Investigating the human immunodeficiency virus type 1-infected monocyte-derived macrophage secretome. Virology (2007) 1.30
Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. J Neurosci (2003) 1.28
Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. J Control Release (2010) 1.28
Nitrated {alpha}-synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets. J Immunol (2009) 1.27
Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. J Neurosci (2009) 1.27
CD8+ cell depletion accelerates HIV-1 immunopathology in humanized mice. J Immunol (2010) 1.27
Cytokine-mediated inhibition of fibrillar amyloid-beta peptide degradation by human mononuclear phagocytes. J Immunol (2008) 1.23
Generation of cytotoxic T cells against virus-infected human brain macrophages in a murine model of HIV-1 encephalitis. J Immunol (2002) 1.23
The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer's disease brain. Arch Immunol Ther Exp (Warsz) (2012) 1.23
Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice. J Infect Dis (2012) 1.23
Loss of neuronal integrity during progressive HIV-1 infection of humanized mice. J Neurosci (2011) 1.22
Regulation of tissue inhibitor of metalloproteinase-1 by astrocytes: links to HIV-1 dementia. Glia (2003) 1.22
Inflammation and adaptive immunity in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.22
CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction. PLoS One (2009) 1.21
Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections. Nanomedicine (2013) 1.21
Innate and adaptive immunity for the pathobiology of Parkinson's disease. Antioxid Redox Signal (2009) 1.20
Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation. J Neurochem (2006) 1.19
Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy. Antimicrob Agents Chemother (2013) 1.17
Design and characterization of ebolavirus GP prehairpin intermediate mimics as drug targets. Protein Sci (2014) 1.16
CSF proteomic fingerprints for HIV-associated cognitive impairment. J Neuroimmunol (2007) 1.16
Neuroprotective mechanisms of lithium in murine human immunodeficiency virus-1 encephalitis. J Neurosci (2005) 1.16
Nitrated alpha-synuclein and microglial neuroregulatory activities. J Neuroimmune Pharmacol (2008) 1.15
Ion channel blockade attenuates aggregated alpha synuclein induction of microglial reactive oxygen species: relevance for the pathogenesis of Parkinson's disease. J Neurochem (2007) 1.15
Neuromodulatory activities of CD4+CD25+ regulatory T cells in a murine model of HIV-1-associated neurodegeneration. J Immunol (2009) 1.14
Neurodegenerative disorders and nanoformulated drug development. Nanomedicine (Lond) (2009) 1.14
Proteomic studies of nitrated alpha-synuclein microglia regulation by CD4+CD25+ T cells. J Proteome Res (2009) 1.13
Cytoskeletal protein transformation in HIV-1-infected macrophage giant cells. J Immunol (2007) 1.13
Sodium phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinson's disease. PLoS One (2012) 1.13
Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease. Nanomedicine (Lond) (2010) 1.12
Macrophage-induced inflammation affects hippocampal plasticity and neuronal development in a murine model of HIV-1 encephalitis. Glia (2005) 1.12
Comparative manufacture and cell-based delivery of antiretroviral nanoformulations. Int J Nanomedicine (2011) 1.11
Immunoregulation of a CB2 receptor agonist in a murine model of neuroAIDS. J Neuroimmune Pharmacol (2010) 1.10
Links between progressive HIV-1 infection of humanized mice and viral neuropathogenesis. Am J Pathol (2010) 1.09
Integrated expression profiles of mRNA and miRNA in polarized primary murine microglia. PLoS One (2013) 1.09
Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery. J Leukoc Biol (2006) 1.08
Impaired spatial cognition and synaptic potentiation in a murine model of human immunodeficiency virus type 1 encephalitis. J Neurosci (2002) 1.08
Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells. Int J Nanomedicine (2012) 1.08
Tracking superparamagnetic iron oxide labeled monocytes in brain by high-field magnetic resonance imaging. J Neurosci Res (2003) 1.08
Copolymer-1 induces adaptive immune anti-inflammatory glial and neuroprotective responses in a murine model of HIV-1 encephalitis. J Immunol (2007) 1.07
Memantine protects hippocampal neuronal function in murine human immunodeficiency virus type 1 encephalitis. J Neurosci (2004) 1.06
UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues. J Chromatogr B Analyt Technol Biomed Life Sci (2011) 1.05
HIV-1 infected monocyte-derived macrophages affect the human brain microvascular endothelial cell proteome: new insights into blood-brain barrier dysfunction for HIV-1-associated dementia. J Neuroimmunol (2007) 1.05
Methamphetamine-associated psychosis. J Neuroimmune Pharmacol (2011) 1.05
Methods development for blood borne macrophage carriage of nanoformulated antiretroviral drugs. J Vis Exp (2010) 1.03
Neuroregulatory events follow adaptive immune-mediated elimination of HIV-1-infected macrophages: studies in a murine model of viral encephalitis. J Immunol (2004) 1.03
Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. Nanomedicine (Lond) (2013) 1.03
Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers. J Control Release (2010) 1.03
Molecular characterization of a putative antiretroviral transcriptional factor, OTK18. J Immunol (2004) 1.02